The Global Diabetes Drugs Market is expected to reach US$ 78,261.7 mn by 2026 owing to rising prevalence of diabetes the world over. Key insights into this growing market have been shared by Fortune Business Insights in its report, titled “Diabetes Drugs Market Size, Share and Global Trend By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) & Geography Forecast till 2026”.
Browse Complete Report Details @
https://www.fortunebusinessinsights.com/industry-reports/diabetes-drugs-market-100570
The report comprehensively analyses the major factors that will influence the growth of the market. Diabetes is a chronic disease in which a person’s blood sugar or blood glucose gets too high. This glucose gets absorbed in the body through a hormone called insulin which is made in the pancreas. Insulin helps glucose enter the body’s cells, which, in turn, give the body energy to function
Get Sample PDF Brochure @
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetes-drugs-market-100570
Some of the Main Key Players Covered in the Report
- Johnson & Johnson
- Bayer Pharmaceuticals
- Novo Nordisk
- Sanofi
- Merck
- Eli Lilly and Company
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim
- Novartis
Undiagnosed Sections May Hinder Market Growth
The Centre for Disease Control and Prevention revealed that around 7.2 mn people in the US remained undiagnosed in 2017. The global diabetes drugs market may see restrained growth as a result, since a large number of people remain untapped.
However, as lifestyles get more sedentary and diagnostic methods get more advanced, the market is sure to gain momentum between 2018 and 2026 and register a CAGR of 6.1%.
Rising Demand for Insulin Treatments to Surge the Market
Insulin provides the one of the most efficient treatment methods for diabetes. As a result, there is a growing demand for low-cost insulin treatments, especially to combat Type 2 diabetes. The rapidly rising insulin segment is, therefore, expected to boost the global diabetes drugs market during the forecast period. This has also encouraged private and public investments in research and development, which, in turn, will accelerate market growth. For example, recently, a rapid-acting, low-cost insulin called Lispro was launched in its generic form by Eli Lilly and Company in the US.
TOC Followed By:
6. North America Diabetes Drugs Market Analysis, Insights and Forecast, 2015-2026
6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast – By Drug Class
6.2.1 Insulin
6.2.2 DPP-4 Inhibitors
6.2.3 GLP-1 Receptor Agonists
6.2.4 SGLT-2 Inhibitors
6.2.5 Others
6.3. Market Analysis, Insights and Forecast – By Diabetes Type
6.3.1 Diabetes 1
6.3.2 Diabetes 2
6.4. Market Analysis, Insights and Forecast – By Route of Administration
6.4.1 Oral
6.4.2 Subcutaneous
6.4.3 Intravenous
6.5. Market Analysis, Insights and Forecast – By Distribution Channel
6.5.1 Online pharmacies
6.5.2 Hospital Pharmacies
6.5.3 Retail Pharmacies
6.6. Market Analysis, Insights and Forecast – By Country
6.6.1 U.S.
6.6.2 Canada
More Trending Topics from Future Business Insights:
Pulse Oximeters Market 2019 Future Demand, Industry Reports, Comprehensive Insights, Outlook by 2025
Coronary Stents Market Global Demand, Emerging Market Regions, Trends Analysis by 2026